KR20190129032A - 인플루엔자 백신 - Google Patents

인플루엔자 백신 Download PDF

Info

Publication number
KR20190129032A
KR20190129032A KR1020197021716A KR20197021716A KR20190129032A KR 20190129032 A KR20190129032 A KR 20190129032A KR 1020197021716 A KR1020197021716 A KR 1020197021716A KR 20197021716 A KR20197021716 A KR 20197021716A KR 20190129032 A KR20190129032 A KR 20190129032A
Authority
KR
South Korea
Prior art keywords
sequence
seq
amino acids
virus
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197021716A
Other languages
English (en)
Korean (ko)
Inventor
아서 영
렌 선
니콜라스 씨 우
Original Assignee
인벡스, 인크.
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인벡스, 인크., 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 인벡스, 인크.
Publication of KR20190129032A publication Critical patent/KR20190129032A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020197021716A 2016-12-28 2017-12-28 인플루엔자 백신 Withdrawn KR20190129032A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662439865P 2016-12-28 2016-12-28
US62/439,865 2016-12-28
US201762550167P 2017-08-25 2017-08-25
US62/550,167 2017-08-25
PCT/US2017/068800 WO2018126060A1 (en) 2016-12-28 2017-12-28 Influenza vaccines

Publications (1)

Publication Number Publication Date
KR20190129032A true KR20190129032A (ko) 2019-11-19

Family

ID=62710906

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197021716A Withdrawn KR20190129032A (ko) 2016-12-28 2017-12-28 인플루엔자 백신

Country Status (10)

Country Link
US (3) US11111277B2 (enExample)
EP (1) EP3562498A4 (enExample)
JP (1) JP2020515283A (enExample)
KR (1) KR20190129032A (enExample)
CN (1) CN111148528A (enExample)
AU (1) AU2017386682A1 (enExample)
BR (1) BR112019013402A2 (enExample)
CA (1) CA3048448A1 (enExample)
MX (1) MX2019007924A (enExample)
WO (1) WO2018126060A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111148528A (zh) 2016-12-28 2020-05-12 英福瓦克思公司 流感疫苗
CA3148026A1 (en) * 2019-08-13 2021-02-18 Vyjayanthi Krishnan Therapeutic agent effectiveness and its route of administration
CN110772635B (zh) * 2019-11-11 2023-01-31 扬州大学 流感病毒小体包被的仿生纳米疫苗及其制备方法
WO2025214372A1 (zh) * 2024-04-08 2025-10-16 康希诺(上海)生物研发有限公司 一种流感mRNA疫苗及其制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1040001A (en) 1909-03-23 1912-10-01 Bofors Gullspaang Ab Breech-loading mechanism for artillery-guns.
US1017917A (en) 1910-12-17 1912-02-20 Joseph E Runner Combination block and tile machine.
US1023874A (en) 1911-10-12 1912-04-23 Thomas J Price Drinking-fountain.
US1042682A (en) 1912-04-17 1912-10-29 Okey J Jackson Toy cycle.
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
AU1449499A (en) 1997-10-31 1999-05-24 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
JP2002507397A (ja) 1998-03-13 2002-03-12 エピミューン，インコーポレイティド Ｈｌａ結合ペプチド及びその使用
WO1999065927A2 (en) 1998-06-17 1999-12-23 Maxygen, Inc. Method for producing polynucleotides with desired properties
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
CA2370413A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
AU785319B2 (en) * 1999-09-16 2007-01-11 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
CN100412190C (zh) 2001-03-15 2008-08-20 复旦大学 乙肝病毒全基因组多聚酶嵌合体的组建方法和应用
JP2004532038A (ja) 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
CA2453880A1 (en) 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US7569225B2 (en) 2002-08-12 2009-08-04 The Council Of The Queensland Institute Of Medical Research Immunogenic lipopeptides comprising T-helper and B-cell epitopes
EP1578432A4 (en) 2002-10-03 2008-07-30 Epimmune Inc HLA BINDING PEPTIDES AND USES THEREOF
US7790374B2 (en) 2003-10-02 2010-09-07 Basf Aktiengesellschaft Process for sequence saturation mutagenesis (SeSaM)
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
JP2008522621A (ja) 2004-12-09 2008-07-03 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 世界的に流行するトリインフルエンザに対して迅速に応答するためのワクチン
CN101193655A (zh) 2005-04-11 2008-06-04 美国政府健康及人类服务部，疾病控制和预防中心 抗大流行性流感病毒株的疫苗
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
WO2007051036A2 (en) 2005-10-26 2007-05-03 Protelix, Inc. Influenza combinatorial antigen vaccine
WO2007066334A1 (en) 2005-12-06 2007-06-14 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
WO2007091387A1 (ja) 2006-02-07 2007-08-16 Nec Corporation Ｈｌａ結合性ペプチド、その前駆体、それをコードするｄｎａ断片および組み換えベクター
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
EP2069376A4 (en) 2006-07-21 2013-10-16 Pharmexa Inc INDUCTION OF CELLULAR IMMUNE RESPONSES TO INFLUENZA VIRUS BY COMPOSITIONS OF PEPTIDES AND NUCLEIC ACIDS
WO2009014919A2 (en) * 2007-07-13 2009-01-29 Iowa State University Research Foundation, Inc. H2n3 influenza a viruses and methods of use
ES2539818T3 (es) 2007-08-02 2015-07-06 Biondvax Pharmaceuticals Ltd. Vacunas contra la gripe multiepitópicas multiméricas
EP3058954B1 (en) 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
CN101575608A (zh) * 2008-05-07 2009-11-11 中国科学院上海生命科学研究院 针对禽流感病毒的重组联合dna疫苗
JP5775451B2 (ja) 2008-06-19 2015-09-09 バリエーション バイオテクノロジーズ インコーポレイティド インフルエンザを処置するための組成物および方法
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
US8865182B2 (en) * 2009-07-31 2014-10-21 Paxvax, Inc. Adenoviral-based vectors
CA2775720A1 (en) 2009-09-30 2011-04-07 Saint Louis University Peptides for inducing heterosubtypic influenza t cell responses
WO2012082803A2 (en) 2010-12-13 2012-06-21 Cel-Sci Corporation Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2012162564A1 (en) 2011-05-25 2012-11-29 Cel-Sci Corporation Method for inducing an immune response and formulations thereof
US9205144B2 (en) * 2011-06-03 2015-12-08 Dana-Farber Cancer Institute, Inc. Identification of conserved peptide blocks in homologous polypeptides
EP2795321A2 (en) 2011-12-23 2014-10-29 Retroscreen Virology Ltd Vaccine - screening method
KR101382244B1 (ko) 2012-03-30 2014-04-08 재단법인 목암생명공학연구소 광범위한 인플루엔자 바이러스의 감염을 방어할 수 있는 ｔ―세포 기반 유니버설 플루 백신
US20140274806A1 (en) * 2013-03-15 2014-09-18 Synthetic Genomics Vaccines Influenza virus reassortment
WO2015151103A1 (en) * 2014-04-03 2015-10-08 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
WO2015157189A1 (en) 2014-04-07 2015-10-15 The Regents Of The University Of California Vaccines and uses thereof
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
CN111148528A (zh) 2016-12-28 2020-05-12 英福瓦克思公司 流感疫苗
WO2019046901A1 (en) 2017-09-08 2019-03-14 The University Of Melbourne METHODS AND COMPOSITIONS FOR PREVENTING INFLUENZA INFECTION

Also Published As

Publication number Publication date
US20230416311A1 (en) 2023-12-28
AU2017386682A1 (en) 2019-07-25
WO2018126060A1 (en) 2018-07-05
CN111148528A (zh) 2020-05-12
US20180230187A1 (en) 2018-08-16
US20220002352A1 (en) 2022-01-06
US11739127B2 (en) 2023-08-29
CA3048448A1 (en) 2018-07-05
BR112019013402A2 (pt) 2020-03-03
US11111277B2 (en) 2021-09-07
MX2019007924A (es) 2020-01-27
JP2020515283A (ja) 2020-05-28
EP3562498A1 (en) 2019-11-06
EP3562498A4 (en) 2020-10-28
US12234263B2 (en) 2025-02-25

Similar Documents

Publication Publication Date Title
JP7384512B2 (ja) 広域インフルエンザウイルスワクチン
BE1023087B1 (fr) Antigenes du cytomegalovirus et leurs utilisations
JP4588296B2 (ja) キメラワクチン
EP2268816B1 (fr) Polynucléotides et polypeptides chimériques permettant la sécrétion d'un polypeptide d'intérêt en association avec des exosomes et leur utilisation pour la production de compositions immunogènes
JP7078620B2 (ja) アレルギーの治療のための核酸
EP2961846B1 (en) Crimean-congo haemorrhagic fever virus antigenic composition
KR20210005046A (ko) T-세포 유도 백신 조성물의 조합물 및 이의 용도
US12234263B2 (en) Influenza vaccines
US20100068226A1 (en) Polynucleotides and Uses Thereof
AU2015292261B2 (en) Constrained proteins and uses therefor
WO2021207730A1 (en) Vaccines for coronavirus and methods of using the same
JP2025179041A (ja) 帯状疱疹ｍＲＮＡワクチン及びその調製方法と使用
US20230174588A1 (en) A vaccine against sars-cov-2 and preparation thereof
CN117083291A (zh) 基于源自SARS-CoV-2 Delta毒株的序列的冠状病毒核酸疫苗
US12398195B2 (en) Lamp constructs comprising allergens
JP2002501369A (ja) Ｆｉｖワクチン
CN116549627A (zh) 基于腺病毒载体的广谱新冠疫苗及其应用
JP2023547656A (ja) がんの腫瘍溶解性ウイルス免疫療法のための免疫チェックポイントを調節するｖｓｖ－ｎｄｖハイブリッドウイルス
RU2808567C2 (ru) Противораковая вакцина с инвариантной цепью из костистых рыб
Murashev et al. Immunogenicity of candidate DNA vaccine based on subtype A of human immunodeficiency virus type 1 predominant in Russia
CN117412769A (zh) 具有复制能力的4型腺病毒sars-cov-2疫苗及其用途
WO2025106754A1 (en) Coronavirus vaccine
US20030118601A1 (en) FIV vaccine

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190724

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination